Trial · NCT05015595
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement of OCD symptoms will be intended as a rate of more then 1/3 on the Y-BOCS total score. | From the week number 5 to the week number 52 | The investigators will evaluate the improvement of symptoms through a decrease of OCD, intended as a rate of more then 1/3 on the Y-BOCS total score. |
| Secondary | Evaluate the minimum effective dose of memantine | From the week number 5 to the week number 46 | The second aim of the study is to evaluate the minimum effective dose of memantine in these patients. The investigators will evaluate the improvement of symptoms through reduction of both subscales (obsessive thoughts and compulsive behaviors) and of the total Y-BOCS score. |
| Secondary | Evaluate the effects after drug withdrawal through follow up | From the week number 5 to the week number 46 | Moreover the investigators will evaluate the effects after drug withdrawal during follow up through reduction of both subscales (obsessive thoughts and compulsive behaviors) and of the total Y-BOCS score. |
| Other | Improvement at the WAIS-IV. | from the week number 5 to the week number 52 | The third aim is to investigate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the WAIS-IV Digit Symbol. |
| Other | Improvement at the Trial Making Test. | from the week number 5 to the week number 52 | The fourth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Trial Making Test. |
| Other | Improvement at the Digit and Corsi Span. | from the week number 5 to the week number 52 | The fifth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Digit and Corsi Span. |
| Other | Improvement at the Corsi Block Tapping test. | from the week number 5 to the week number 52 | The sixth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Corsi Block Tapping test. |
| Other | Improvement at the Story recall of Rivermead Behavioral Memory Test. | from the week number 5 to the week number 52 | The sixth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Story recall of Rivermead Behavioral Memory Test. |
| Other | Improvement at the Babcock Story recall test. | from the week number 5 to the week number 52 | The eighth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Story recall of Babcock Story recall test. |
| Other | Improvement at the Stroop Task. | from the week number 5 to the week number 52 | The ninth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Stroop Task. |
| Other | Improvement at the Tower of London. | from the week number 5 to the week number 52 | The tenth aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the Tower of London. |
| Other | Improvement at the the Modified Five Point Test. | from the week number 5 to the week number 52 | The eleventh aim is to evaluate the effect of memantine on patients without cognitive impairment, on improvement of cognitive functions through the reduction of total score of the the Modified Five Point Test. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05015595/registered